Holen Sie sich die Stockscreener-App
2.96
2.78%
0.08
Schlusskurs vom Vortag:
$2.88
Offen:
$2.82
24-Stunden-Volumen:
1.13M
Relative Volume:
0.91
Marktkapitalisierung:
$263.02M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-8.64%
1M Leistung:
-25.16%
6M Leistung:
+66.29%
1J Leistung:
+0.00%
1-Tages-Spanne:
$2.82
$2.99
1-Wochen-Bereich:
$2.82
$3.34
52-Wochen-Spanne:
$1.42
$4.66
Atyr Pharma Inc Stock (ATYR) Company Profile
Firmenname
Atyr Pharma Inc
Sektor
Branche
Telefon
(858) 731-8389
Adresse
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Vergleichen Sie ATYR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
2.96 | 263.02M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-18 | Eingeleitet | Leerink Partners | Outperform |
| 2025-01-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-04 | Eingeleitet | Wells Fargo | Overweight |
| 2024-09-05 | Eingeleitet | Jefferies | Buy |
| 2023-07-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-10-12 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-09-21 | Eingeleitet | Piper Sandler | Overweight |
| 2021-05-10 | Eingeleitet | Laidlaw | Buy |
| 2020-08-17 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | Eingeleitet | ROTH Capital | Buy |
| 2020-03-02 | Eingeleitet | Oppenheimer | Outperform |
| 2018-02-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2017-09-07 | Eingeleitet | Piper Jaffray | Overweight |
| 2016-12-13 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2015-12-16 | Eingeleitet | Citigroup | Neutral |
| 2015-06-01 | Eingeleitet | Citigroup | Buy |
| 2015-06-01 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Atyr Pharma Inc Aktie (ATYR) Neueste Nachrichten
Charles Schwab Investment Management Inc. Takes Position in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
ATyr Pharma : ClearOne, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results - MarketScreener
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
aTyr Pharma Strengthens Drug Development Team with New Equity Compensation Package - Stock Titan
Is aTyr Pharma (ATYR) The Hot Biotech Stock Under $5? - Insider Monkey
aTyr Pharma appoints new head for efzofitimod program By Investing.com - Investing.com South Africa
aTyr Pharma appoints new head for efzofitimod program - Investing.com
ATyr Pharma Announces The Appointment Of Dalia R. Rayes As Head Of Commercial, Global Efzofitimod Franchise - MarketScreener
aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise - GlobeNewswire
25-Year Pharma Veteran Joins aTyr to Launch First New Sarcoidosis Treatment in 70 Years - Stock Titan
Victory Capital Management Inc. Buys New Stake in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
Insider Buying: Jane Gross Acquires Additional Shares of aTyr Ph - GuruFocus.com
10 Hot Biotech Stocks Under $5 - Insider Monkey
Is aTyr Pharma (ATYR) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Atyr, FDA align on efzofitimod trial analysis for pulmonary sarcoidosis - Sarcoidosis News
aTyr Pharma (ATYR) Stock Soars 24% on Promising Drug Developments - Markets Insider
Reviewing Atyr PHARMA (NASDAQ:ATYR) & Windtree Therapeutics (NASDAQ:WINT) - Defense World
HC Wainwright Reaffirms Buy Rating for Atyr PHARMA (NASDAQ:ATYR) - Defense World
Atyr PHARMA INC (NASDAQ:ATYR) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Earnings call transcript: aTyr Pharma Q4 2024 beats EPS expectations By Investing.com - Investing.com Australia
aTyr Pharma’s Earnings Call Highlights Progress and Challenges - TipRanks
aTyr Pharma: Good Safety Data In Pulmonary Sarcoidosis, Institutions Are Accumulating - Seeking Alpha
Cantor Fitzgerald maintains Overweight on aTyr Pharma stock - Investing.com India
aTyr Pharma Inc (ATYR) Q4 2024 Earnings Call Highlights: Strong Cash Position and Promising ... - Yahoo Finance
aTyr Pharma shares fall as Q4 loss narrows - Investing.com India
aTyr Pharma Inc (ATYR) Q4 2024 Earnings Call Highlights: Strong Cash Position and Promising ... By GuruFocus - Investing.com Canada
aTyr Pharma Inc (ATYR) Q4 2024 Earnings Call Highlights: Strong Cash Position and Promising Clinical Developments - GuruFocus.com
aTyr Pharma Reports 2024 Results and Strategic Progress - TipRanks
Earnings call transcript: aTyr Pharma Q4 2024 beats EPS expectations - Investing.com
aTyr Pharma Inc Reports Q4 2024 Earnings: EPS of -$0.18 Beats Es - GuruFocus.com
aTYR PHARMA INC SEC 10-K Report - TradingView
aTyr Pharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Atyr Pharma: Q4 Earnings Snapshot - mySA
aTyr Pharma shares fall as Q4 loss narrows By Investing.com - Investing.com South Africa
ATYR PHARMA Earnings Results: $ATYR Reports Quarterly Earnings - Nasdaq
aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update - GlobeNewswire
aTyr Pharma Hits Major Phase 3 Milestone with $94M War Chest for Sarcoidosis Drug - StockTitan
aTyr Pharma’s efzofitimod shows promise in ILD treatment By Investing.com - Investing.com Canada
aTyr Pharma’s efzofitimod shows promise in ILD treatment - Investing.com India
aTyr Pharma Announces Publication Demonstrating - GlobeNewswire
aTyr Pharma Announces Publication Demonstrating Efzofitimod's Immunomodulatory Activity in Science Translational Medicine - The Manila Times
Breakthrough: New Science Study Reveals How Efzofitimod Fights Chronic Inflammation - StockTitan
aTyr Pharma, Inc. to Host Earnings Call - ACCESS Newswire
Atyr Pharma Shares Rise After Lung Disease Treatment Passes Safety Review - MarketWatch
aTyr Pharma: Attractive Buy Opportunity Amid Positive Phase 2 Data and Anticipated Phase 3 Catalysts - TipRanks
aTyr rises after safety update on lead program - Seeking Alpha
aTyr Pharma Announces Fourth Positive DSMB Review for - GlobeNewswire
aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis - The Manila Times
Can This Rare Disease Drug's Perfect Safety Record Signal a Breakthrough for Sarcoidosis Patients? - StockTitan
Finanzdaten der Atyr Pharma Inc-Aktie (ATYR)
Es liegen keine Finanzdaten für Atyr Pharma Inc (ATYR) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
2.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):